BRIEF-Nuvo pharmaceuticals to study Pennsaid 2 pct
July 13 (Reuters) - Nuvo Pharmaceuticals Inc
* Nuvo Pharmaceuticals Inc. announces Pennsaid 2 percent phase 3 trial to support regulatory approvals in the E.U., Canada and Australia
* Will conduct a new placebo-controlled, multi-centre phase 3 trial in Germany to study Pennsaid 2 percent for treatment of acute ankle sprains Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.